Rise in pediatric head and neck MRSA infections in USA

26 January 2009

A study published in the January 19 issue of the Archives of Otolaryngology - Head and Neck Surgery shows that there was a nationwide  increase in the prevalence of pediatric methicillin-resistant  Staphylococcus aureus head and neck infections from January 2001 to  December 2006.

The increase in antibiotic-resistant infections has become a big concern  for researchers and clinicians over the years. MRSA was once a condition  that was only found in hospital settings. However, over the last decade  the number of outbreaks has grown among patients without risk factors.

In an attempt to identify trends in the susceptibility of  antibiotic-resistant infections, researchers from the USA's Emory  University School of Medicine and Children's Healthcare of Atlanta  studied data on pediatric patients from nationwide hospitals. They  reviewed a total of 21,009 pediatric head and neck S. aureus infections  from 300 hospitals nationwide that occurred between January 1, 2001 and  December 31, 2006.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight